1. India Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited

ADVENZYMES.NS
Advanced Enzyme Technologies LimitedIN flagNational Stock Exchange of India
329.85
INR
+5.50
- -
36.94BMarket Cap
Advanced Enzyme Technologies Limited
ADVENZYMES.NS
(National Stock Exchange of India)

Recent

price

329.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
11.2
16.52
20.6
19.71
20.41
26.89
29.69
34.75
37.42
39.54
44.8
47.32
48.33
55.76
56.91
- -
66.66
Revenue per Share
1.61
3.26
4.68
1.81
4.68
6.97
8.27
8.07
9.95
11.58
13.06
10.7
9.45
11.92
11.72
- -
15.08
Basic EPS, GAAP
-2.31
-10.81
0.93
4.22
3.32
7.79
8.76
9.53
10.41
8.08
12.84
8.42
9.14
8.85
9.63
- -
- -
Free Cash Flow per Basic Share
0.01
0.12
0.27
0.37
0.16
0.33
0.23
0.68
0.72
0.94
0.71
1.06
1.12
5.07
5.28
- -
- -
Dividend per Share
5.87
8.9
12.89
14.26
18.73
25.55
33.5
40.81
50.15
60.87
73.42
83.17
91.64
98.53
105.09
- -
115.03
Book Value per Share
6.21
-5.44
-0.47
- -
3.82
10.13
20.2
22.32
32.73
45.56
59.91
69.6
80.71
88.31
96.82
- -
113.22
Tangible Book Value per Share
104
104
107
109
109
109
111
112
112
112
112
112
112
112
112
- -
112
Basic Weighted Avg Shares
1,161
1,713
2,194
2,145
2,221
2,926
3,287
3,879
4,177
4,416
5,004
5,289
5,404
6,235
6,365
7,450
7,458
Sales/Revenue/Turnover
16.18
34.03
38.44
32.87
37.11
44.72
42.82
38.63
39.44
40.58
41.86
31.87
25.59
27.72
25.23
25.78
25.34
Operating Margin (%)
50
55
74
100
90
87
128
183
211
258
287
350
350
352
366
401
401
Depreciation Expense
167
338
498
197
510
758
915
901
1,111
1,293
1,459
1,196
1,056
1,333
1,311
1,687
1,687
Net Income, GAAP
11.65
28.36
34.2
26.17
30.74
35.06
32.18
32.68
28.44
25.74
28
27.63
26.02
27.08
28.5
25.34
25.34
Effective Tax Rate (%)
14.36
19.71
22.7
9.2
22.95
25.92
27.86
23.22
26.59
29.28
29.16
22.61
19.55
21.38
20.6
22.65
22.62
Profit Margin (%)
184
-280
-82
-406
-266
268
777
1,119
2,169
3,160
4,485
5,399
6,435
7,031
7,836
9,369
9,369
Working Capital
370
1,394
1,167
879
540
388
195
198
70
120
138
265
224
228
209
117
117
LT Debt
645
984
1,657
1,711
2,164
3,359
4,852
5,817
7,048
8,674
10,326
11,404
12,842
13,711
14,687
16,831
16,831
Total Equity
- -
19.24
16.96
15.15
17.08
22.05
19.58
17.02
16.95
16.2
15.38
10.92
8.21
9.19
7.82
8.89
8.75
Return on Invested Capital (%)
- -
19.57
17.53
7.72
17.16
22.42
22.33
18.13
18.7
18.72
17.17
12.12
10.29
11.44
10.64
12.59
12.59
Return on Capital (%)
- -
44.1
43.4
13.49
28.39
31.48
28.22
21.79
21.87
20.86
19.46
13.67
10.81
12.54
11.51
13.7
13.7
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
187
- -
204
LT Borrowings
87
- -
79
LT Finance Leases
72
- -
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
- -
112
Market Capitalization
36,445
33,805
28,563

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
9,335
- -
10,436
Cash, Cash Equivalents & STI
6,190
- -
7,072
Accounts Receivable, Net
1,253
- -
1,450
Inventories
1,734
- -
1,773
Total Current Liabilities
1,067
- -
1,067
Payables & Accruals
- -
- -
- -
ST Debt
187
- -
204
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.91%
10.31%
14.6%
Free Cash Flow
4.66%
-4.64%
-3.08%
Net Income, GAAP
9.52%
4.7%
28.68%
Sales/Revenue/Turnover
9.94%
8.47%
17.04%
Total Cash Common Dividend
59.65%
82.38%
1.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,473
1,578
1,609
1,574
6,235
2025
1,545
1,461
1,691
1,672
6,365
2026
1,859
1,845
1,719
2,034
7,450

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.58
3.08
3.74
- -
11.92
2025
3.05
2.94
3.36
2.37
11.72
2026
3.57
3.87
3.8
3.84
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5.07
2025
- -
- -
- -
- -
5.28
2026
- -
- -
- -
- -
- -
Similar Companies
Sugai Chemical Industry Co., Ltd. (4120.T)
Hainan Development Holdings Nanhai Co., Ltd. (002163.SZ)
Allied Supreme Corp. (4770.TW)
Nippon Chemical Industrial Co., Ltd. (4092.T)
Shanghai Kinlita Chemical Co., Ltd. (300225.SZ)
Zhejiang Jiaao Enprotech Stock Co., Ltd (603822.SS)
Business
Advanced Enzyme Technologies Limited is an India-based biotech company primarily engaged in the research, development, manufacturing, and marketing of enzyme and probiotic products. The company offers over 400 proprietary products derived from more than 65 indigenous enzymes and probiotics. It serves multiple industries, including human healthcare and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, leather processing, paper and pulp processing, biofuels, biomass processing, and biocatalysis. Key product categories include nutraceuticals; food and feed enzymes; dietary supplements; functional beverages and foods; and specialty enzymes like Addzyme CALB, which is a food-grade lipase enzyme used in triglyceride hydrolysis. Founded in 1989 and headquartered in Nashik, Maharashtra, India, Advanced Enzyme Technologies operates globally with a focus on eco-safe biochemical solutions. Recent strategic developments include the acquisition and equity investment in its wholly owned subsidiary Advanced Nutrazyme Private Limited, aimed at expanding its presence in the nutraceutical segment. The company has also been actively enhancing its renewable energy usage and sustainability initiatives, including the installation of solar power plants at its manufacturing facilities. Additionally, it pursues new product launches and broadens its geographical footprint to capture emerging market opportunities. Advanced Enzyme Technologies is noted for its strong research and development focus driving innovation across its enzyme and probiotic product portfolio. The enterprise is positioned as a leader in enzyme technology with operational footholds and markets across India and international regions. It targets diverse customers ranging from large-scale food processing firms and pharmaceutical companies to animal nutrition providers, positioning itself as a comprehensive solutions provider in enzymology and related biotechnologies. Overall, the company combines a legacy of over three decades with modern strategic expansions in product lines and sustainable operational practices to maintain and grow its market leadership in the enzyme manufacturing and nutraceuticals sectors.